Drug Eluting Balloon Market, by Product Type (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon, and Others), by End User (Hospitals, CATH Laboratories, Ambulatory Surgery Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Drug eluting balloons are angioplasty balloons that are coated with an anti-proliferative drug, which is eluted in vessel walls during the inflation of balloon, usually at nominal pressure with a specific minimal inflation time. The active substance coated on the drug eluting balloon should be lipophilic in nature to have a high absorption rate through the vessel wall. Mostly paclitaxel is used as active ingredient due to its high pharmacokinetic transfer rate into the vessel wall and it is actively used in drug eluting balloons in the U.S. market and has been already approved for use in Europe. Drug-coated balloons (DCB), also referred to as drug-eluting balloons (DEB), were created as a way to reduce very high restenosis rates in peripheral vessels. They also have been investigated in clinical trials to prevent coronary artery in-stent restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs are also used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude. Angioplasty using percutaneous coronary intervention techniques revealed satisfying result compared to conservative medical treatment.
Market Dynamics
Increasing product launches by key players in market are expected to drive the global drug eluting balloon market growth. For instance, in October 2019, Koninklijke Philips N.V., a health technology company, launched two new Stellarex Drug-Coated Balloon Sizes. Royal Philips introduced two new balloons to its Stellarex 0.035” low-dose drug-coated balloon (DCB) portfolio. The new 200mm and 150mm Stellarex 0.035” low-dose DCBs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of de novo and restenotic lesions in native superficial femoral or popliteal arteries, both arteries in the upper leg. The new balloons broadened physicians’ treatment options for peripheral artery disease (PAD) patients with a high risk of restenosis and expand the Stellarex portfolio.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook